Naiara Perurena

Oct 9, 2024 | nature.com | Naiara Perurena |Yoona Yang |Carrie Rodriguez |Alycia Gardner |Patrick Loi |Yilin Xu | +9 more

AbstractTriple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6.

Apr 7, 2023 | cell.com | Naiara Perurena |Rachel Davis |Srivatsan V. Raghavan |Rebecca Lock

Antibodies Anti-Mcl-1 Cell Signaling Technology Cat#5453; RRID: AB_10694494 Anti-Mcl-1 Cell Signaling Technology Cat#94296; RRID: AB_2722740 Anti-Mcl-1 Santa Cruz Biotechnology Cat#sc-819; RRID: AB_2144105 Anti-Mcl-1 Santa Cruz Biotechnology Cat#sc-12756; RRID: AB_627915 Anti-Mcl-1 Abcam Cat#ab32087; RRID: AB_776245 Anti-Bcl-xL Cell Signaling Technology Cat#2762; RRID: AB_10694844 Anti-Bcl-xL Cell Signaling Technology Cat#2764; RRID: AB_2228008 Anti-BIM Cell Signaling Technology Cat#2819;...